Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Morin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 2/20 | 1.00 |
| ▸ | MEN1 known ✓ | O00255 | 8/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 4/20 | 0.97 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 3/20 | 0.97 |
| ▸ | SYK known ✓ | P43405 | 3/20 | 0.97 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.73 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.73 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.73 |
| ▸ | ALOX5 known ✓ | P09917 | 2/20 | 0.73 |
| ▸ | GSK3A known ✓ | P49840 | 2/20 | 0.73 |
| ▸ | GSK3B known ✓ | P49841 | 2/20 | 0.73 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.67 |
| ▸ | PIK3CG known ✓ | P48736 | 2/20 | 0.66 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.66 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.65 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.65 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.65 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.65 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morin SCHEMBL7116848 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL29400568 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL15106661 | 1.00 | MPG (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL29435805 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL29929115 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL10335390 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL19984 | 0.98 | MEN1 (1.00) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL21874430 | 0.97 | MEN1 (0.97) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL8165525 | 0.93 | MEN1 (0.89) | MPGTHRBMEN1KMT2AXDH | |
| Morin SCHEMBL5248628 | 0.91 | MEN1 (0.89) | MPGTHRBMEN1KMT2AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | claimed |
| EP-4593859-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | Eresina, LLC (US) | 2025-08-06 | — | — | EP | claimed |
| CN-119950483-A | Application of morin hydrate in preparation of anti-respiratory syncytial virus drugs | 湖北江夏实验室 | 2025-05-09 | — | — | CN | claimed |
| CN-116712470-B | Pharmaceutical composition for preventing and treating fowl leukocrown disease | 中国农业科学院兰州畜牧与兽药研究所 | 2025-03-07 | — | — | CN | claimed |
| WO-2024073013-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024073011-A1 | TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA, LLC (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240085670-A1 | METHODS OF MAKING A LOW-COST MINIATURE ACCOMMODATING OPTICAL IMAGING SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | claimed |
| EP-4157245-A1 | PHOTOCURABLE RESIN FOR HIGH-RESOLUTION 3-D PRINTING | United States Government as Represented by The Department of Veterans Affairs (US) | 2023-04-05 | — | — | EP | claimed |
| CN-109908127-B | Application of compounds in preparation of anti-small RNA virus drugs | 中山大学附属第六医院 | 2022-02-01 | — | — | CN | claimed |
| US-20210371597-A1 | PHOTOCURABLE RESIN FOR HIGH-RESOLUTION 3-D PRINTING | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2021-12-02 | — | — | US | claimed |
| WO-2011142832-A2 | STEM CELLS DERIVED UNDER LOW OXYGEN CONDITIONS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-17 | — | — | WO | claimed |
| WO-2011106222-A2 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | CORNING INCORPORATED (US) | 2011-09-01 | — | — | WO | claimed |
| US-20110207219-A1 | MODIFIED SUBSTRATES FOR PROTECTION OF PEPTIDE-IMMOBILIZED SURFACES FROM GAMMA RADIATION DEGRADATION | CORNING INCORPORATED | 2011-08-25 | — | — | US | claimed |
| US-20080132484-A1 | Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 | CYCLACEL LIMITED (GB) | 2008-06-05 | — | — | US | claimed |
| US-7261857-B2 | Colorimetric artificial nose having an array of dyes and method for artificial olfaction | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-08-28 | — | — | US | claimed |
| EP-1683056-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | Cyclacel Limited (GB) | 2006-07-26 | — | — | EP | claimed |
| WO-2005047526-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | CYCLACEL LIMITED (GB) | 2005-05-26 | — | — | WO | claimed |
| US-20040152073-A1 | Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2004-08-05 | — | — | US | claimed |
| US-20030180719-A1 | Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-25 | — | — | US | claimed |
| US-20030143112-A1 | Colorimetric artificial nose having an array of dyes and method for artificial olfaction | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | THRB 3769/4885MEN1 4053/4885HDAC6 3261/4885 |
| US-20080132484-A1 | Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 | PLK2, PLK4, PLK1 | THRB 3052/4885MEN1 3178/4885HDAC6 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.